Selected research
Industry Research
Biologics CDMO Industry Research Report 2026
Market perspective
The global Biologics CDMO market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Biologics CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Biologics CDMO is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Biologics CDMO is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Biologics CDMO include AGC, Boehringer Ingelheim, Fujifilm Diosynth Biotechnologies, ICON Plc, Samsung Biologics, Toyobo, AbbVie, Lonza Group AG and Thermo Fisher Scientific, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Biologics CDMO market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Biologics CDMO Market by Company
AGC
Boehringer Ingelheim
Fujifilm Diosynth Biotechnologies
ICON Plc
Samsung Biologics
Toyobo
AbbVie
Lonza Group AG
Thermo Fisher Scientific
WuXi Biologics
Biologics CDMO Segment by Type
Biological Agent
Biosimilar Drug
Biologics CDMO Segment by Application
Cell Therapy
Drug Development
Others
Biologics CDMO Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biologics CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Biologics CDMO manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Biologics CDMO by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Biologics CDMO in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Biological Agent
- Biosimilar Drug
Applications
- Cell Therapy
- Drug Development
- Others
Companies covered
- AGC
- Boehringer Ingelheim
- Fujifilm Diosynth Biotechnologies
- ICON Plc
- Samsung Biologics
- Toyobo
- AbbVie
- Lonza Group AG
- Thermo Fisher Scientific
- WuXi Biologics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Biologics CDMO Market Size (2021-2032)
- 2.2.2 Global Biologics CDMO Sales (2021-2032)
- 2.2.3 Global Biologics CDMO Market Average Price (2021-2032)
- 2.3 Biologics CDMO by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Biological Agent
- 2.3.3 Biosimilar Drug
- 2.4 Biologics CDMO by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Cell Therapy
- 2.4.3 Drug Development
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Biologics CDMO Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Biologics CDMO Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Biologics CDMO Revenue of Manufacturers (2021-2026)
- 3.4 Global Biologics CDMO Average Price by Manufacturers (2021-2026)
- 3.5 Global Biologics CDMO Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Biologics CDMO, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Biologics CDMO, Product Type & Application
- 3.8 Global Manufacturers of Biologics CDMO, Established Date
- 3.9 Global Biologics CDMO Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 AGC
- 4.1.1 AGC Company Information
- 4.1.2 AGC Business Overview
- 4.1.3 AGC Biologics CDMO Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 AGC Biologics CDMO Product Portfolio
- 4.1.5 AGC Recent Developments
- 4.2 Boehringer Ingelheim
- 4.2.1 Boehringer Ingelheim Company Information
- 4.2.2 Boehringer Ingelheim Business Overview
- 4.2.3 Boehringer Ingelheim Biologics CDMO Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Boehringer Ingelheim Biologics CDMO Product Portfolio
- 4.2.5 Boehringer Ingelheim Recent Developments
- 4.3 Fujifilm Diosynth Biotechnologies
- 4.3.1 Fujifilm Diosynth Biotechnologies Company Information
- 4.3.2 Fujifilm Diosynth Biotechnologies Business Overview
- 4.3.3 Fujifilm Diosynth Biotechnologies Biologics CDMO Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Fujifilm Diosynth Biotechnologies Biologics CDMO Product Portfolio
- 4.3.5 Fujifilm Diosynth Biotechnologies Recent Developments
- 4.4 ICON Plc
- 4.4.1 ICON Plc Company Information
- 4.4.2 ICON Plc Business Overview
- 4.4.3 ICON Plc Biologics CDMO Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 ICON Plc Biologics CDMO Product Portfolio
- 4.4.5 ICON Plc Recent Developments
- 4.5 Samsung Biologics
- 4.5.1 Samsung Biologics Company Information
- 4.5.2 Samsung Biologics Business Overview
- 4.5.3 Samsung Biologics Biologics CDMO Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Samsung Biologics Biologics CDMO Product Portfolio
- 4.5.5 Samsung Biologics Recent Developments
- 4.6 Toyobo
- 4.6.1 Toyobo Company Information
- 4.6.2 Toyobo Business Overview
- 4.6.3 Toyobo Biologics CDMO Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Toyobo Biologics CDMO Product Portfolio
- 4.6.5 Toyobo Recent Developments
- 4.7 AbbVie
- 4.7.1 AbbVie Company Information
- 4.7.2 AbbVie Business Overview
- 4.7.3 AbbVie Biologics CDMO Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 AbbVie Biologics CDMO Product Portfolio
- 4.7.5 AbbVie Recent Developments
- 4.8 Lonza Group AG
- 4.8.1 Lonza Group AG Company Information
- 4.8.2 Lonza Group AG Business Overview
- 4.8.3 Lonza Group AG Biologics CDMO Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Lonza Group AG Biologics CDMO Product Portfolio
- 4.8.5 Lonza Group AG Recent Developments
- 4.9 Thermo Fisher Scientific
- 4.9.1 Thermo Fisher Scientific Company Information
- 4.9.2 Thermo Fisher Scientific Business Overview
- 4.9.3 Thermo Fisher Scientific Biologics CDMO Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Thermo Fisher Scientific Biologics CDMO Product Portfolio
- 4.9.5 Thermo Fisher Scientific Recent Developments
- 4.10 WuXi Biologics
- 4.10.1 WuXi Biologics Company Information
- 4.10.2 WuXi Biologics Business Overview
- 4.10.3 WuXi Biologics Biologics CDMO Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 WuXi Biologics Biologics CDMO Product Portfolio
- 4.10.5 WuXi Biologics Recent Developments
5 Global Biologics CDMO Market Scenario by Region
- 5.1 Global Biologics CDMO Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Biologics CDMO Sales by Region: 2021-2032
- 5.2.1 Global Biologics CDMO Sales by Region: 2021-2026
- 5.2.2 Global Biologics CDMO Sales by Region: 2027-2032
- 5.3 Global Biologics CDMO Revenue by Region: 2021-2032
- 5.3.1 Global Biologics CDMO Revenue by Region: 2021-2026
- 5.3.2 Global Biologics CDMO Revenue by Region: 2027-2032
- 5.4 North America Biologics CDMO Market Facts & Figures by Country
- 5.4.1 North America Biologics CDMO Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Biologics CDMO Sales by Country (2021-2032)
- 5.4.3 North America Biologics CDMO Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Biologics CDMO Market Facts & Figures by Country
- 5.5.1 Europe Biologics CDMO Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Biologics CDMO Sales by Country (2021-2032)
- 5.5.3 Europe Biologics CDMO Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Biologics CDMO Market Facts & Figures by Country
- 5.6.1 Asia Pacific Biologics CDMO Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Biologics CDMO Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Biologics CDMO Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Biologics CDMO Market Facts & Figures by Country
- 5.7.1 South America Biologics CDMO Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Biologics CDMO Sales by Country (2021-2032)
- 5.7.3 South America Biologics CDMO Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Biologics CDMO Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Biologics CDMO Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Biologics CDMO Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Biologics CDMO Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Biologics CDMO Sales by Type (2021-2032)
- 6.1.1 Global Biologics CDMO Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Biologics CDMO Sales Market Share by Type (2021-2032)
- 6.2 Global Biologics CDMO Revenue by Type (2021-2032)
- 6.2.1 Global Biologics CDMO Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Biologics CDMO Revenue Market Share by Type (2021-2032)
- 6.3 Global Biologics CDMO Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Biologics CDMO Sales by Application (2021-2032)
- 7.1.1 Global Biologics CDMO Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Biologics CDMO Sales Market Share by Application (2021-2032)
- 7.2 Global Biologics CDMO Revenue by Application (2021-2032)
- 7.2.1 Global Biologics CDMO Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Biologics CDMO Revenue Market Share by Application (2021-2032)
- 7.3 Global Biologics CDMO Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Biologics CDMO Value Chain Analysis
- 8.1.1 Biologics CDMO Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Biologics CDMO Production Mode & Process
- 8.2 Biologics CDMO Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Biologics CDMO Distributors
- 8.2.3 Biologics CDMO Customers
9 Global Biologics CDMO Analyzing Market Dynamics
- 9.1 Biologics CDMO Industry Trends
- 9.2 Biologics CDMO Industry Drivers
- 9.3 Biologics CDMO Industry Opportunities and Challenges
- 9.4 Biologics CDMO Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst